Václavík Jan
Vnitr Lek. 2017 Summer;63(5):333-337.
These review article presents the results of major recent studies in cardiovascular prevention. HOPE-3 study showed that people with medium cardiovascular risk who have not experienced a cardiovascular event, and have normal blood pressure, benefit from deploying a statin, and in the presence of hypertension benefit from deploying a combination of a statin and antihypertensive drugs. Studies evaluating genetic predisposition brought new evidence that both LDL cholesterol and systolic blood pressure are independent and multiplicative causal risk factors for cardiovascular events. A mild long-term reduction in blood pressure and LDL cholesterol has the potential to significantly reduce the lifetime risk of cardiovascular events. In the final section the article discusses options for improving patient adherence to antihypertensive and lipid treatment and the new available fixed combinations for these diseases.Key words: arterial hypertension - cardiovascular prevention - dyslipidemia - fixed combinations - treatment.
这篇综述文章介绍了近期心血管疾病预防领域的主要研究成果。HOPE-3研究表明，心血管风险中等、未发生心血管事件且血压正常的人群，服用他汀类药物有益；而存在高血压的人群，联合使用他汀类药物和抗高血压药物有益。评估遗传易感性的研究带来了新证据，即低密度脂蛋白胆固醇和收缩压都是心血管事件的独立且相乘的因果风险因素。血压和低密度脂蛋白胆固醇的轻度长期降低有可能显著降低心血管事件的终生风险。文章最后一部分讨论了提高患者对抗高血压和降脂治疗依从性的方法，以及这些疾病新可用的固定复方制剂。关键词：动脉高血压 - 心血管预防 - 血脂异常 - 固定复方制剂 - 治疗
